Tags

Type your tag names separated by a space and hit enter

Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.
Clin Vaccine Immunol. 2011 Sep; 18(9):1503-9.CV

Abstract

Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines for HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and young adults. A total of 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV coadministered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV, and longitudinal changes of antibody titers (ABTs) at 1, 2, 6, and 12 months for all vaccines. Groups 1 and 2 had similar CD4 counts and HIV RNA levels during the study. The seroconversion rate for PV was 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in groups 1 and 2 for both PV and SV. The side effects of vaccination were mild and mostly local. In HIV-infected children, adolescents, and young adults, the immune response triggered by a single dose of PV was similar to that obtained with a double dose and was associated with long-term antibody response.

Authors+Show Affiliations

Pediatric Clinic, L. Sacco Hospital, University of Milan, G.B. Grassi, 74-20157 Milan, Italy. alessandra.vigano@unimi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21795458

Citation

Viganò, Alessandra, et al. "Long-term Immunogenicity After One and Two Doses of a Monovalent MF59-adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered With the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial." Clinical and Vaccine Immunology : CVI, vol. 18, no. 9, 2011, pp. 1503-9.
Viganò A, Giacomet V, Pariani E, et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin Vaccine Immunol. 2011;18(9):1503-9.
Viganò, A., Giacomet, V., Pariani, E., Giani, E., Manfredini, V., Bedogni, G., Erba, P., Amendola, A., Zanetti, A., & Zuccotti, G. (2011). Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clinical and Vaccine Immunology : CVI, 18(9), 1503-9. https://doi.org/10.1128/CVI.05200-11
Viganò A, et al. Long-term Immunogenicity After One and Two Doses of a Monovalent MF59-adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered With the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial. Clin Vaccine Immunol. 2011;18(9):1503-9. PubMed PMID: 21795458.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. AU - Viganò,Alessandra, AU - Giacomet,Vania, AU - Pariani,Elena, AU - Giani,Elisa, AU - Manfredini,Valeria, AU - Bedogni,Giorgio, AU - Erba,Paola, AU - Amendola,Antonella, AU - Zanetti,Alessandro, AU - Zuccotti,Gianvincenzo, Y1 - 2011/07/27/ PY - 2011/7/29/entrez PY - 2011/7/29/pubmed PY - 2012/1/13/medline SP - 1503 EP - 9 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 18 IS - 9 N2 - Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines for HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and young adults. A total of 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV coadministered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV, and longitudinal changes of antibody titers (ABTs) at 1, 2, 6, and 12 months for all vaccines. Groups 1 and 2 had similar CD4 counts and HIV RNA levels during the study. The seroconversion rate for PV was 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in groups 1 and 2 for both PV and SV. The side effects of vaccination were mild and mostly local. In HIV-infected children, adolescents, and young adults, the immune response triggered by a single dose of PV was similar to that obtained with a double dose and was associated with long-term antibody response. SN - 1556-679X UR - https://www.unboundmedicine.com/medline/citation/21795458/Long_term_immunogenicity_after_one_and_two_doses_of_a_monovalent_MF59_adjuvanted_A/H1N1_Influenza_virus_vaccine_coadministered_with_the_seasonal_2009_2010_nonadjuvanted_Influenza_virus_vaccine_in_HIV_infected_children_adolescents_and_young_adults_in_a_randomized_controlled_trial_ L2 - http://cvi.asm.org/cgi/pmidlookup?view=long&pmid=21795458 DB - PRIME DP - Unbound Medicine ER -